| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10309125 | Schizophrenia Research | 2015 | 6 Pages |
Abstract
The SERMs, raloxifene and tamoxifen, can prevent dopamine D1/D2 receptor-mediated disruptions of sensorimotor gating, similar to oestradiol. These data lend support for the use of SERMs as a treatment for schizophrenia.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Andrea Gogos, Maarten van den Buuse,